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ABSTRACT
Unwanted side-effects of a drug therapy are well known to oral medicine specialists and other colleagues. Usually they 
manifest itself  as dry mouth, taste disturbances, various allergic or toxic reactions on the lips and/or in the oral cavity. 
However, the list of the drugs which might induce unwanted reactions is everyday becoming longer as more and more 
drugs are introduced on the market. Certain problems when diagnosing and reporting unwanted side effects of the drugs 
exist as only accurate method of diagnosis is repeated drug use in controlled clinical setting where fatal consequences 
due to the anaphilactic shock could be avoided. We report a side effect reaction to tiotropium bromide (Spiriva®) cap 
used with HandiHaler manifesting itself  as an oral ulceration in a 65 yrs old male. On the third day of drug intake the 
patient developed oral ulceration two times in a period of few months. Other medications he has been using for several 
years. To our knowledge this is a first report as an oral side-effect of this drug used for treatment of chronic obstructive 
pulmonary disease (COPD).
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INTRODUCTION
Virtually every drug has the potential to cause adverse reac-
tions on the oral mucosa but some have greater ability to 
do so. So far, a  wide range of drugs have been recognized 
as potential inducers of unwanted adverse reactions in the 
oral cavity. Smith and Burtner (1) reviewed such reactions 
after administration of  200 most frequently prescribed 
drugs and reported that the most freuquent ones were dry 
mouth (80.5%), dysgeusia (47.5%) and stomatitis (33.9%). 
However, other reactions to numerous drugs such as swe-
llings, hypersalivation, discoloration of saliva, white lesions, 
oral burns, fixed drugs eruptions, mucositis, neoplasms, 
pemphigus and pemphigoid reactions and other bullous di-
sorders, mucosal pigmentation, lichenoid reactions, cheilitis, 
neuropathies, and halitosis have been reported throughout 
the literature (2).
Drug-related aphthous-like ulceration have been reported 
after the use of beta blockers such as labetalol, captopril, 
nicorandil and non-steroidal anti-inflammatory drugs 
(NSAID). Also such reactions have been described after the 
use of mycophenolate or sirolimus, sodium lauryl sulfate, 
protease inhibitors, tacrolimus and sulfonamides, though the 
exact pathogenic mechanisms are unclear in all of these. A 
case control study has now confirmed the association of oral 
ulceration with NSAIDs and beta blockers, whereas all the 
other data are obtained from case reports, small series and 
non-peer-reviewed reports (2). Recently, we have reported a 
case report of a delayed contact sensitivity on the lips and 
oral mucosa due to propolis (3). 
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CASE REPORT
The patient, 65 years old was reviewed on the annual appo-
intment for long-standing oral lichen planus at the Depar-
tment of Oral medicine, University of Queensland. At the 
time his lesions of oral lichen planus were barely visible and 
only discrete whitish lines were seen on the lateral left side of 
the tongue. However, during the examination, he reported 
development of the ulceration in the vestibular mucosa in 
the region 41 and 42 which started after he took the third 
cap (by use of HandiHaler) of tiotropium bromide for his 
COPD symptoms. At the closer inspection the ulceration has 
now been in healing phase (Figure 1). Additionally patient 
reported that last time he was using tiotropium bromide also 
after 3 days of therapy, the ulceration developed. Given the 
clear relationship between appearence of the lesion and the 
administration of tiotropium bromide the patient was advi-
sed to stop taking it. The lesion resolved after ten days. De-
tailed medical history revealed that he suffered heart attack 
before 18 years and he had blood transfusion eleven years 
ago. From time to time he has lower back pain. Apart from 
that he has been using the same medications throughout 
many years such as diltiazem hydrochloride (Cardizem®; 
240 mg/day), isosorbide dinitrate (Isordil®; 5mg/6x a day), 
candesartan cilexetil (Atacand®; 8mg/day), perindopril er-
bumine (Coversyl® plus; 4/1.25 a day), aspirin (Astrix®; 100 
mg/day), biperiden hydrochloride (Akineton®; 2mg/day). 
To date, 3 months from our patients last review no such 
lesions developed and patient stopped taking tiotropium 
bromide. A biopsy was not taken because there was a clear 
relationship between the drug use and oral lesion.
DISCUSSION
Long-acting bronchodilators are the mainstream for the 
treatment of COPD nowadays, and in the last 3 years tio-
tropium bromide has been put on the market in Western 
countries (1). So far, it has been documented that tiotropium 
bromide results in dry mouth in approximatelly 10-16% of 
the patients which is reversible and rarely causes disconti-
nuation of therapy (2). Additionally drug may have various 
side effects involving skin (rash, urticaria and pruritus), 
urinary difficulties and retention, constipation, blurred vi-
sion and glaucoma, increased heart rate and cough as well 
as throat iritation. Also hypersensitivity reactions including 
isolated cases of angioedema have been reported (4). Most 
recently, subacute cutaneous lupus erythematosus through 
inhalation route has been described in one patient and 
paralytic ileus in another (5,6). Despite enhanced specific 
chemical effects of muscarinic drugs, side-effects on other 
organs can not be avoided completely as confirmed in this 
case report.
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Fig. 1. Healed ulceration in the anterior lower mandibular vesti-
bule which started to develop three days after tiotropium bromide 
intake.
